New strategies with Zevalin (R) consolidation in the treatment of non-Hodgkin lymphomas

作者：Robu D; Huglo D; Tricot S; Malek E; Jouet J P; Morschhauser F^*

来源：Medecine Nucleaire-Imagerie Fonctionnelle et Metabolique, 2009, 33(8): 491-498.

DOI：10.1016/j.mednuc.2009.06.007

• Radio-immunotherapy
• Consolidation
• Zevalin (R)
• Non-Hodgkin lymphoma

Radio-immunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin (R)) has been first approved in 2004 as a treatment for patients with relapsed/refractory non-Hodgkin follicular lymphoma (FL). In April 2008, the label has been extended to the consolidation therapy after remission induction in previously untreated patients with FL on the basis of the First-line indolent trial (FIT) phase III randomised Study of Zevalin (R) its front-line consolidation versus no further treatment. Consolidation of first remission with Zevalin (R) (15 MBq/kg), 6 to 12 weeks after the last chemotherapy dose in advanced-stage FL is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in 77% PR-to-CR conversion rates regardless of type of first-line induction treatment. An assessment of the dosimetry of 90-Y ibritumomab tiuxetan in the FIT study indicated that consolidation treatment was safe in all patients, including those with a CR after induction therapy. The consolidation strategy with Zevalin (R), as a single agent or combined with high-dose chemotherapy followed by autologous stem cell transplantation is currently investigated in other types of B-cell lymphomas.

• 出版日期2009-8